Subscribe To
Iovance biotherapeutics: testing shareholders' patience
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on ...
October 22, 2023, 9:12 am
Jim jordan loses secret ballott to remain house speaker nominee
Yesterday, it seemed like there was a way forward where McHenry would be empowered as speaker until January and Jordan would have until then to lock d...
October 20, 2023, 6:03 pm
Beam to reprioritize portfolio, slash jobs, shares tank
BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate...
October 20, 2023, 12:47 pm
Dow jones newswires: daiichi sankyo shares jump on multibillion-dollar drug development deal with merck
Daiichi Sankyo shares rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck to jointly develop and commercialize t...
October 20, 2023, 8:59 am
Biomarin: growth drivers remain intact
During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline include...
October 19, 2023, 11:04 pm
Daiichi sankyo shares jump on multibillion-dollar drug development deal with merck
Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly d...
October 19, 2023, 10:40 pm
Terns pharmaceuticals to participate in upcoming investor conferences
FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stag...
October 19, 2023, 8:05 pm
Daiichi sankyo and merck team up on $22 bln collaboration for sankyo's antibody drug conjugates
Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) ...
October 19, 2023, 7:46 pm
Intellia's (ntla) ind for gene-editing therapy gets fda clearance
Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to tre...
October 19, 2023, 12:47 pm
1 cheap chip stock that's a buy-the-dip candidate
Microchip stock has fallen more than the overall market the last couple of months, and understanding interest-rate moves is essential. Debt remains a ...
October 19, 2023, 6:35 am
Lisata's (lsta) lead cancer drug gets ec's orphan tag, stock up
Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from t...
October 18, 2023, 12:47 pm
Evelo (evlo) drops 59% on flunking psoriasis drug study
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical dev...
October 18, 2023, 12:47 pm
Nkarta (nktx) rallies 112% as fda clears ind for lupus drug
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidat...
October 18, 2023, 12:03 pm
Stock movers: united airlines shares drop after warning on fuel costs and middle east conflict
Shares of Viking Therapeutics Inc. VKTX, -0.37% rallied nearly 11% following early clinical study data showing its drug ...
October 18, 2023, 5:57 am
Cyclarity therapeutics announces clinical advisory board
NOVATO, Calif, Oct. 17, 2023 (GLOBE NEWSWIRE) — Cyclarity Therapeutics, Inc. (https://cyclaritytx.com), today announced its newly formed Clinical Ad...
October 17, 2023, 10:04 pm
Jim jordan won't be speaker on the first vote
It took Kevin McCarthy 15 votes to get elected as speaker so it's not over for Jordan but we'll see how it goes from here. Congress is voting and he's...
October 17, 2023, 5:18 pm
Viking therapeutics' stock rallies following early drug study data
Viking Therapeutics Inc. VKTX, -0.37% shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clini...
October 17, 2023, 4:56 pm
Magnite is a recovery candidate
Magnite's stock has fallen due to a rough patch in the CTV and digital ad market, but it's well placed to benefit from a recovery in the market. The c...
October 17, 2023, 1:07 am
Apollomics announces presentations of vebreltinib data at esmo 2023
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical co...
October 16, 2023, 10:55 pm
Intellia's (ntla) hae candidate gets ema's prime designation
The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA...
October 16, 2023, 2:17 pm